Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials

Current Medical Research and Opinion

Volumn 26, Issue 7, 2010, Pages 1621-1628

  Fonseca, Vivian ^a   Davidson, Jaime ^b   Home, Philip ^c   Snyder, James ^d   Jellinger, Paul ^e   Dyhr Toft, Anders ^f   Barnett, Anthony ^g  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d Center for Diabetes and Endocrine Care ^*

^e Center for Diabetes and Endocrine Care   (United States)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Blood glucose; Insulin aspart; Insulin detemir; Insulin glargine; Pooled analysis; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; ANTIDIABETIC AGENT; DRUG COMBINATION; DRUG DOSAGE FORM; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BODY MASS; CLINICAL TRIAL; CONFOUNDING VARIABLE; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; AGED; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; POSTPRANDIAL STATE; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 77953601896     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.485087     Document Type: Article

References (16)

1. Rodbard HW, Blonde L, Braithwaite SS, et al. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl. 1):1-68.
2. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyper-glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
3. Holman RR, Thorne KI, Farmer AJ, et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730
4. Raskin P, Matfin G, Schwartz SL, et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin Plus Oral agents). Diabet Obes Metab 2009;11:27-32.
5. Rosenstock J, Davies M, Home PD, et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-416
6. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274
7. Garber A, Wahlen J, Wahl T, et al. for the 1-2-3 study group. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66.
8. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-1581
9. Raskin P, Allen E, Hollander P, et al. for the INITIATE study group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265
10. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-259
11. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
12. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal\+ prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre-and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-2364
13. Malone JK, Kerr LF, Campaigne BN, et al. Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-2044
14. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22:374-381
15. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8: 448-455
16. Kazda C, Hü lstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20: 145-152